Automated identification of molecular effects of drugs (AIMED).

Journal: Journal of the American Medical Informatics Association : JAMIA
Published Date:

Abstract

INTRODUCTION: Genomic profiling information is frequently available to oncologists, enabling targeted cancer therapy. Because clinically relevant information is rapidly emerging in the literature and elsewhere, there is a need for informatics technologies to support targeted therapies. To this end, we have developed a system for Automated Identification of Molecular Effects of Drugs, to help biomedical scientists curate this literature to facilitate decision support.

Authors

  • Safa Fathiamini
    School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
  • Amber M Johnson
    Center for Computational Biomedicine, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Public Health Science, Medical University of South Carolina, 135 Cannon Street, Suite 303, Charleston, SC 29425, USA and Department of Investigational Cancer Therapeutics, Institute for Personalized Cancer Therapy, UT-MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.3044, Houston, TX 77030, USA.
  • Jia Zeng
    Center for Computational Biomedicine, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Public Health Science, Medical University of South Carolina, 135 Cannon Street, Suite 303, Charleston, SC 29425, USA and Department of Investigational Cancer Therapeutics, Institute for Personalized Cancer Therapy, UT-MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.3044, Houston, TX 77030, USA.
  • Alejandro Araya
    School of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
  • Vijaykumar Holla
    Center for Computational Biomedicine, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Public Health Science, Medical University of South Carolina, 135 Cannon Street, Suite 303, Charleston, SC 29425, USA and Department of Investigational Cancer Therapeutics, Institute for Personalized Cancer Therapy, UT-MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.3044, Houston, TX 77030, USA.
  • Ann M Bailey
    Center for Computational Biomedicine, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Public Health Science, Medical University of South Carolina, 135 Cannon Street, Suite 303, Charleston, SC 29425, USA and Department of Investigational Cancer Therapeutics, Institute for Personalized Cancer Therapy, UT-MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.3044, Houston, TX 77030, USA.
  • Beate C Litzenburger
    Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nora S Sanchez
    Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yekaterina Khotskaya
    Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hua Xu
    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Funda Meric-Bernstam
    Center for Computational Biomedicine, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Public Health Science, Medical University of South Carolina, 135 Cannon Street, Suite 303, Charleston, SC 29425, USA and Department of Investigational Cancer Therapeutics, Institute for Personalized Cancer Therapy, UT-MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.3044, Houston, TX 77030, USA.
  • Elmer V Bernstam
    Center for Computational Biomedicine, School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA, Department of Public Health Science, Medical University of South Carolina, 135 Cannon Street, Suite 303, Charleston, SC 29425, USA and Department of Investigational Cancer Therapeutics, Institute for Personalized Cancer Therapy, UT-MD Anderson Cancer Center, 1400 Holcombe Blvd., FC8.3044, Houston, TX 77030, USA.
  • Trevor Cohen
    University of Washington, Seattle, WA.